Autoantibodies to Interferon‐γ in a Patient with Selective Susceptibility to Mycobacterial Infection and Organ‐Specific Autoimmunity | Zendy

Rainer Döffinger | Zendy; MATTHEW HELBERT | Zendy; Gabriela BarcenasMorales | Zendy; Kun Yang | Zendy; Stéphanie BoissonDupuis | Zendy; Lourdes CeronGutierrez | Zendy; Clara Espitia-Pinzón | Zendy; Neil Barnes | Zendy; Graham Bothamley | Zendy; JeanLaurent Casanova | Zendy; Hilary Longhurst | Zendy; Dinakantha Kumararatne | Zendy

Open Access

Autoantibodies to Interferon‐γ in a Patient with Selective Susceptibility to Mycobacterial Infection and Organ‐Specific Autoimmunity

Author(s) -

Rainer Döffinger,

MATTHEW HELBERT,

Gabriela BarcenasMorales,

Kun Yang,

Stéphanie BoissonDupuis,

Lourdes CeronGutierrez,

Clara Espitia-Pinzón,

Neil Barnes,

Graham Bothamley,

JeanLaurent Casanova,

Hilary Longhurst,

Dinakantha Kumararatne

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/380453

Subject(s) - medicine , autoantibody , immunology , autoimmunity , tuberculosis , mycobacterium tuberculosis , peripheral blood mononuclear cell , mycobacterium chelonae , interferon , antibody , mycobacterium , in vitro , pathology , biology , biochemistry

We evaluated a patient with disseminated Mycobacterium tuberculosis and Mycobacterium chelonae infection, of which he died. He also developed autoimmune (type I) diabetes and primary hypothyroidism. His serum contained a high titer of immunoglobulin G autoantibody to interferon-gamma (IFN-gamma) capable of blocking in vitro responses to this cytokine by peripheral blood mononuclear cells from normal donors. These results suggest that autoantibodies to IFN-gamma can induce susceptibility to disseminated mycobacterial infection, which may be refractory to chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research